Product Description
a Salivary Substitute and a Mucoprotective Product (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01316393)
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Camurus AB
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Xerostomia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HS-10-404 | P4 |
Completed |
Xerostomia |
2011-05-01 |